Royalty Pharma has acquired the rights to certain royalties payable on sales of the pharmacologic stress agent Lexiscan and the antibiotic Cubicin from an undisclosed seller for a cash payment of $487 million.

Lexiscan (regadenoson) is a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Lexiscan was co-developed by CV Therapeutics (now Gilead) and Astellas, said the New York City-based Royalty Pharma.

Cubicin (daptomycin for injection) is a bacteriocidal, IV antibiotic with activity against MRSA, or methicillin-resistant staphylococcus aureus, added the company.